Intravitreal bevacizumab in inflammatory ocular neovascularization

被引：62

作者：

Mansour, Ahmad M. ^{[1
]}

Mackensen, Friederike ^{[3
]}

Arevalo, J. Fernando ^{[4
]}

Ziemssen, Focke ^{[5
]}

Mahendradas, Padmamalini ^{[6
,7
]}

Mehio-Sibai, Abla ^{[2
,8
]}

Hrisomalos, Nicholas ^{[9
]}

Lai, Timothy Y. Y. ^{[10
]}

Dodwell, David ^{[11
]}

Chan, Wai-Man ^{[12
]}

Ness, Thomas ^{[13
]}

Banker, Alay S. ^{[14
,15
]}

Pai, Sivakami A. ^{[6
,7
]}

Berrocal, Maria H. ^{[16
]}

Tohme, Rania ^{[6
,7
]}

Heiligenhaus, Arnd ^{[17
]}

Bashshur, Ziad F. ^{[1
]}

Khairallah, Moncef ^{[18
]}

Salem, Khalil M. ^{[1
]}

Hrisomalos, Frank N. ^{[9
]}

Wood, Matthew H. ^{[19
]}

Heriot, Wilson ^{[20
]}

Adan, Alfredo

Kumar, Atul ^{[21
,22
]}

Lim, Lyndell ^{[23
]}

Hall, Anthony ^{[20
,24
]}

Becker, Matthias ^{[3
]}

机构：

[1] Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon

[2] Rafic Hariri Univ Hosp, Beirut, Lebanon

[3] Heidelberg Univ, Interdisciplinary Uveitis Ctr, Heidelberg, Germany

[4] Univ Los Andes, Clin Oftalmol Ctr Caracas, Caracas, Venezuela

[5] Univ Tubingen, Dept Ophthalmol, Tubingen, Germany

[6] Narayana Nethralaya, Dept Uveitis, Tuebingen Bevacizumab Study Grp, Bangalore, Karnataka, India

[7] Narayana Nethralaya, Dept Retina, Bangalore, Karnataka, India

[8] Amer Univ Beirut, Dept Epidemiol & Populat Hlth, Beirut, Lebanon

[9] Indiana Univ, Dept Ophthalmol, Indianapolis, IN 46204 USA

[10] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China

[11] Springfield Eye Clin, Springfield, IL USA

[12] Chinese Univ Hong Kong, Dept Ophthalmol, Hong Kong Sanat & Hosp, Happy Valley, Hong Kong, Peoples R China

[13] Univ Eye Hosp, Freiburg, Germany

[14] Bankers Retina Clin, Ahmadabad, Gujarat, India

[15] Ctr Laser, Ahmadabad, Gujarat, India

[16] Univ Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA

[17] St Franziskus Hosp, Uveitis Ctr, Dept Ophthalmol, Munster, Germany

[18] Fattouma Bourguiba Univ Hosp, Dept Ophthalmol, Monastir, Tunisia

[19] Eye Surg Associates, Lincoln, NE USA

[20] Cabrini Med Ctr, Dept Surg, Malvern, Vic, Australia

[21] Univ Barcelona, Hosp Clin Barcelona, Dept Ophthalmol, Barcelona, Spain

[22] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India

[23] Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia

[24] Alfred Hosp, Dept Ophthalmol, Melbourne, Vic, Australia

来源：

AMERICAN JOURNAL OF OPHTHALMOLOGY | 2008年 / 146卷 / 03期

关键词：

D O I：

10.1016/j.ajo.2008.05.024

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

PURPOSE: To assess the role of bevacizumab in inflammatory ocular neovascularization. DESIGN: Retrospective, multicenter, consecutive case series of inflammatory ocular neovascularization. METHODS: Patients with inflammatory ocular neovascularization of varying causes for whom standard therapy failed were treated with intravitreal injection of bevacizumab. Main outcome measures included improvement of best,corrected visual acuity (BCVA) expressed in logarithm of minimum angle of resolution units, response of inflammatory ocular neovascularization by funduscopy and angiography, and decrease in central foveal thickness as measured by optical coherence tomography at the three-month follow-up. RESULTS: At the three,month follow-up, 84 eyes of 79 patients had been treated with a mean of 1.3 injections (range, one to three). Thirty-four eyes showed juxtafoveal choroidal neovascularization (CNV), 34 eyes showed subfoveal CNV, eight eyes showed peripapillary CNV, and I I eyes showed neovascularization of the disc (NVD) or neovascularization elsewhere (NVE). BCVA improved 2.4 lines from 0.68 (6/28 or 20/94) to 0.44 (6/17 or 20/55) (P < .001). BCVA improved by one to three lines in 34.5% of the eyes, by four to six lines in 16.7% of the eyes, and by more than six lines in 14.2% of the eyes. Function was unchanged in 23.8% of the eyes. BCVA worsened in 10.7% (zero to three lines in 7.1%, more than four lines in 3.6%). Central foveal thickness decreased from baseline 346 to 252 mu m (P < .001). For CNV, 32 eyes (43.2%) had complete regression after the injection, 27 (36.5%) had partial regression, five (6.8%) had no response, and 10 eyes (13.5%) were not evaluated by the contributors. For NVD or NVE, seven eyes (63.6%) had complete regression of new vessels and four eyes (36.4%) had partial regression after the injection. CONCLUSIONS: Intravitreal bevacizumab led to short-term significant visual improvement and regression of inflammatory ocular neovascularization in a wide variety of inflammatory ocular diseases.

引用

页码：410 / 416

页数：7

共 26 条

[21] Massive vascular endothelium growth factor (VEGF) expression in Eales' disease [J].

Perentes, Y ;

Chan, CC ;

Bovey, E ;

Uffer, S ;

Herbort, CP .

KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2002, 219 (04) :311-314

[22] Photodynamic therapy with verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study [J].

Rosenfeld, PJ ;

Saperstein, DA ;

Bressler, NM ;

Reaves, TA ;

Sickenberg, M ;

Rosa, RH ;

Sternberg, P ;

Aaberg, TM ;

Aaberg, TM .

OPHTHALMOLOGY, 2004, 111 (09) :1725-1733

[23]

Shah Parag K., 2007, Indian Journal of Ophthalmology, V55, P75

[24] THE EVOLUTION OF ARGON-LASER PHOTOCOAGULATION SCARS IN PATIENTS WITH THE OCULAR HISTOPLASMOSIS SYNDROME [J].

SHAH, SS ;

SCHACHAT, AP ;

MURPHY, RP ;

FINE, SL .

ARCHIVES OF OPHTHALMOLOGY, 1988, 106 (11) :1533-1536

[25] Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity [J].

Travassos, Antonio ;

Teixeira, Susana ;

Ferreira, Pinto ;

Regadas, Isaura ;

Travassos, Ana Sofia ;

Esteves Esperancinha, Florindo ;

Prieto, Isabel ;

Pires, Graca ;

Van Velze, Robert ;

Valido, A. ;

do Ceu Machado, Maria .

OPHTHALMIC SURGERY LASERS & IMAGING, 2007, 38 (03) :233-237

[26] Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases [J].

Wachtlin, J ;

Heimann, H ;

Behme, T ;

Foerster, MH .

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2003, 241 (11) :899-906

← 1 2 3 →